MY209207A - Escherichia coli compositions and methods thereof - Google Patents

Escherichia coli compositions and methods thereof

Info

Publication number
MY209207A
MY209207A MYPI2021000906A MYPI2021000906A MY209207A MY 209207 A MY209207 A MY 209207A MY PI2021000906 A MYPI2021000906 A MY PI2021000906A MY PI2021000906 A MYPI2021000906 A MY PI2021000906A MY 209207 A MY209207 A MY 209207A
Authority
MY
Malaysia
Prior art keywords
methods
escherichia coli
compositions
modified
coli
Prior art date
Application number
MYPI2021000906A
Inventor
Wei Chen
Nishith Merchant
Karen Kiyoko Takane
Scott Ellis Lomberk
Ling Chu
Suddham Singh
Mark Edward Ruppen
Avvari Krishna Prasad
Rosalind Pan
Justin Keith Moran
Jason Arnold Lotvin
Srinivas Kodali
Jin-Hwan Kim
Jianxin Gu
Laurent Oliver Chorro
Annaliesa Sybil Anderson
Robert G K Donald
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY209207A publication Critical patent/MY209207A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1228—Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G)
    • C07K16/1232—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

In one aspect, the invention relates to an immunogenic composition comprising modified Opolysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
MYPI2021000906A 2018-08-24 2019-08-20 Escherichia coli compositions and methods thereof MY209207A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862722370P 2018-08-24 2018-08-24
US201862784940P 2018-12-26 2018-12-26
US201962881361P 2019-07-31 2019-07-31
PCT/IB2019/057025 WO2020039359A2 (en) 2018-08-24 2019-08-20 Escherichia coli compositions and methods thereof

Publications (1)

Publication Number Publication Date
MY209207A true MY209207A (en) 2025-06-27

Family

ID=68172237

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2021000906A MY209207A (en) 2018-08-24 2019-08-20 Escherichia coli compositions and methods thereof

Country Status (18)

Country Link
US (3) US11260119B2 (en)
EP (1) EP3840777A2 (en)
JP (2) JP2021534304A (en)
KR (1) KR102666639B1 (en)
CN (1) CN112566658B (en)
AU (1) AU2019325400B2 (en)
BR (1) BR112021002530A2 (en)
CA (1) CA3110134A1 (en)
CO (1) CO2021001926A2 (en)
IL (2) IL281094B2 (en)
MX (2) MX2021001182A (en)
MY (1) MY209207A (en)
PE (1) PE20211095A1 (en)
PH (1) PH12021550319A1 (en)
SG (1) SG11202101158TA (en)
TW (2) TWI782226B (en)
WO (1) WO2020039359A2 (en)
ZA (1) ZA202100469B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
KR20220143910A (en) * 2020-02-23 2022-10-25 화이자 인코포레이티드 Escherichia coli composition and method thereof
PE20231385A1 (en) 2020-09-17 2023-09-12 Janssen Pharmaceuticals Inc COMPOSITIONS OF MULTIVALENT VACCINES AND USES THEREOF
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
MX2023004912A (en) * 2020-10-27 2023-05-16 Pfizer Compositions and methods thereof.
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
CN116940590A (en) * 2020-12-23 2023-10-24 辉瑞公司 Coli FIMH mutants and uses thereof
US20220236283A1 (en) * 2021-01-28 2022-07-28 Janssen Pharmaceuticals, Inc. Method for identification and quantification of polysaccharides in complex glycoconjugate compositions
MX2023011697A (en) 2021-04-01 2023-10-19 Janssen Pharmaceuticals Inc Production of e. coli o18 bioconjugates.
CN121569027A (en) * 2023-07-21 2026-02-24 葛兰素史克生物有限公司 Immunogenic compositions
TW202602467A (en) 2024-03-11 2026-01-16 美商輝瑞股份有限公司 Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
US20260061042A1 (en) 2024-03-26 2026-03-05 Pfizer Inc. Polynucleotide compositions and uses thereof

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
AU651949B2 (en) 1989-07-14 1994-08-11 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
DE69016129T2 (en) 1989-08-18 1995-05-24 Akzo Nobel Nv Vaccine against Escherichia coli.
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
ATE128628T1 (en) 1990-08-13 1995-10-15 American Cyanamid Co FIBER HEMAGGLUTININ FROM BORDETELLA PERTUSSIS AS A CARRIER FOR CONJUGATE VACCINE.
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
JP3506431B2 (en) 1992-05-06 2004-03-15 プレジデント アンド フェローズ オブ ハーバード カレッジ Diphtheria toxin receptor binding domain
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
DE69313134T2 (en) 1992-06-25 1998-02-26 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTIES
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
DK0616034T3 (en) 1993-03-05 2005-02-21 Wyeth Corp Plasmid for the preparation of CRM protein and diphtheria toxin
KR100310510B1 (en) 1993-03-23 2002-07-04 장 스테판느 Vaccine composition containing 3-0-deacetylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
FR2726003B1 (en) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech CULTURE MEDIUM OF AVIAN TOTIPOTENT EMBRYONIC CELLS, METHOD FOR CULTURING THESE CELLS, AND AVIAN TOTIPOTENT EMBRYONIC CELLS
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6749831B1 (en) 1997-05-16 2004-06-15 Medical Defense Technology, Llc Vaccine against lipopolysaccharide core
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
BR9909915A (en) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Adjuvant compositions
US6858211B1 (en) 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
CA2338093C (en) 1998-07-20 2010-11-30 Shousun C. Szu Vaccines against escherichia coli o157 infection
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (en) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. ADJUSTMENT SYSTEMS AND VACCINES.
CA2355364C (en) 1998-12-21 2014-03-18 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
PL205041B1 (en) 1998-12-23 2010-03-31 Id Biomedical Corp Isolated polynucleotide, vector comprising isolated polynucleotide, vector transformed or transfected host cell, method for production of isolated polypeptide coded by isolated polynucleotide, isolated polypeptide, chimeric polypeptide, composition for vaccines and its use in treating streptococcus infection
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
DE60044236D1 (en) 1999-02-17 2010-06-02 Csl Ltd IMMUNOGENIC COMPLEXES AND METHODS RELATED TO THEM
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
DK1187629T3 (en) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
HK1045713A1 (en) 1999-07-13 2002-12-06 Medimmune, Inc. Donor strand complemented pilin and adhesin broad-based vaccines
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (en) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. Use of the combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
WO2001098334A2 (en) 2000-06-20 2001-12-27 Shire Biochem Inc. Streptococcus antigens
AU2001271907A1 (en) 2000-07-07 2002-01-21 Medimmune, Inc. FimH adhesin proteins and methods of use
AU2002218927B2 (en) 2001-01-04 2007-08-30 The University Of British Columbia Enterohemorrhagic Escherichia coli vaccine
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
MXPA05009579A (en) 2003-03-13 2005-11-17 Glaxosmithkline Biolog Sa Purification process for bacterial cytolysin.
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
JP2008506789A (en) 2004-07-18 2008-03-06 シーエスエル、リミテッド Immunostimulatory complex and oligonucleotide formulation for inducing enhanced interferon-gamma response
EP1776105A2 (en) 2004-07-18 2007-04-25 Coley Pharmaceutical Group, Ltd Methods and compositions for inducing innate immune responses
EP1789454B1 (en) * 2004-08-12 2017-07-05 Lipoxen Technologies Limited Fractionation of charged polysaccharide
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
IL308456A (en) 2005-04-08 2024-01-01 Wyeth Llc Multivalent pneumococcal polysacharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US20100251416A1 (en) 2007-05-22 2010-09-30 Basf Plant Science Gmbh Plants with increased tolerance and/or resistance to environmental stress and increased biomass production
EA200901578A1 (en) 2007-06-26 2010-08-30 Глаксосмитклайн Байолоджикалс С.А. VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
AU2010264538B2 (en) * 2009-06-22 2013-10-03 Wyeth Llc Immunogenic compositions of Staphylococcus aureus antigens
WO2011041003A2 (en) 2009-06-22 2011-04-07 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
CA2768343A1 (en) 2009-07-16 2011-01-20 Novartis Ag Detoxified escherichia coli immunogens
PT2493498T (en) 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
WO2011138361A1 (en) 2010-05-06 2011-11-10 Glycovaxyn Capsular gram-positive bacteria bioconjugate vaccines
WO2012001004A1 (en) 2010-07-02 2012-01-05 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Fimh vaccine against urinary tract infections (uti)
WO2013164334A1 (en) 2012-05-04 2013-11-07 Universiteit Gent Escherichia coli vaccine
DK2859013T3 (en) 2012-06-12 2016-12-19 Fina Biosolutions Llc DIFFERENTIAL functionalization of polymers having AMINO-OXY reagents for diagnostic assays
CA2879272A1 (en) 2012-07-16 2014-01-23 Robert G.K. DONALD Saccharides and uses thereof
PT2885007T (en) * 2012-08-16 2018-12-10 Pfizer Glycoconjugation processes and compositions
KR20150068998A (en) 2012-10-12 2015-06-22 글리코박신 아게 Methods of host cell modification
EP2917351B1 (en) 2012-11-07 2018-12-19 GlaxoSmithKline Biologicals S.A. Production of recombinant vaccine in e. coli by enzymatic conjugation
RU2672053C2 (en) 2012-12-20 2018-11-09 Пфайзер Инк. Glycoconjugation process
HUE038915T2 (en) 2013-01-17 2018-12-28 Arsanis Biosciences Gmbh Mdr e. coli specific antibody
WO2015010185A1 (en) 2013-07-26 2015-01-29 University Of Saskatchewan Methods for producing salmonella o- antigen capsules, compositions and uses thereof
US9415101B2 (en) 2013-09-25 2016-08-16 Sequoia Sciences, Inc. Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
US9504743B2 (en) 2013-09-25 2016-11-29 Sequoia Sciences, Inc Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
BR112016007727A8 (en) 2013-10-11 2018-01-30 Glycovaxyn Ag host cell, and method for producing an unglycosylated protein.
IL312327B2 (en) 2014-01-21 2026-02-01 Pfizer Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
NZ723328A (en) 2014-02-24 2018-01-26 Glycovaxyn Ag Compositions comprising e. coli o25b antigen, uses thereof and methods of manufacture
CN106659799B (en) 2014-07-25 2020-07-17 碧奥辛斯有限责任公司 Glycoconjugate vaccines comprising a basic unit of a molecular construct expressing a built-in plurality of epitopes for the preparation of a broad spectrum vaccine against infections caused by enteropathogenic bacteria
US20160015797A1 (en) 2014-08-06 2016-01-21 Pasteur Institute of Iran (IPI) VACCINE FOR UTI WITH TRUNCATED FORM OF FLAGELLIN (FliC) FROM ENTEROAGGREGATIVE ESCHERICHIA COLI FUSED WITH FimH PROTEIN
US9988426B2 (en) 2014-09-18 2018-06-05 University Of Maryland, Baltimore Broad spectrum conjugate vaccine to prevent Klebsiella pneumoniae and Pseudomonas aeruginosa infections
US9814769B2 (en) 2014-09-30 2017-11-14 Qatar University Vaccines against pathogenic Escherichia coli and methods of using the same
WO2016115328A1 (en) 2015-01-14 2016-07-21 Washington University Vaccine compositions for use against enterotoxigenic escherichia coli
WO2016168324A1 (en) 2015-04-13 2016-10-20 University Of Maryland, Baltimore Compositions and methods for producing bacterial conjugate vaccines
KR102143534B1 (en) 2015-05-04 2020-08-12 화이자 인코포레이티드 Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
US10722580B2 (en) 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
TWI715617B (en) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 Methods and compositions for immune protection against extra-intestinal pathogenic e. coli
US10786561B2 (en) 2015-11-20 2020-09-29 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN119242587A (en) 2017-02-17 2025-01-03 隆萨有限公司 Multisite-specific integration of difficult-to-express proteins into cells
GB201711635D0 (en) 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
TW201946650A (en) 2018-03-12 2019-12-16 美商詹森藥物公司 Vaccines against intra-abdominal infections
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2020375214B2 (en) 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof
MY209568A (en) 2020-01-16 2025-07-22 Janssen Pharmaceuticals Inc Fimh mutant, compositions therewith and use thereof
KR20220143910A (en) 2020-02-23 2022-10-25 화이자 인코포레이티드 Escherichia coli composition and method thereof
MX2023004912A (en) 2020-10-27 2023-05-16 Pfizer Compositions and methods thereof.
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof

Also Published As

Publication number Publication date
ZA202100469B (en) 2024-09-25
TW202023609A (en) 2020-07-01
MX2023013526A (en) 2024-01-08
AU2019325400B2 (en) 2024-04-04
US11260119B2 (en) 2022-03-01
MX2021001182A (en) 2021-04-19
SG11202101158TA (en) 2021-04-29
TW202302140A (en) 2023-01-16
US12128095B2 (en) 2024-10-29
CA3110134A1 (en) 2020-02-27
TWI831394B (en) 2024-02-01
US20200061177A1 (en) 2020-02-27
IL310402A (en) 2024-03-01
CN112566658B (en) 2025-12-19
TWI782226B (en) 2022-11-01
CO2021001926A2 (en) 2021-05-31
IL281094B1 (en) 2024-03-01
AU2019325400A1 (en) 2021-02-18
WO2020039359A3 (en) 2020-04-09
PE20211095A1 (en) 2021-06-14
PH12021550319A1 (en) 2021-10-04
BR112021002530A2 (en) 2021-05-11
WO2020039359A2 (en) 2020-02-27
IL281094A (en) 2021-04-29
KR20210049866A (en) 2021-05-06
US20250121044A1 (en) 2025-04-17
US20220168410A1 (en) 2022-06-02
IL281094B2 (en) 2024-07-01
JP2021534304A (en) 2021-12-09
EP3840777A2 (en) 2021-06-30
JP2024156772A (en) 2024-11-06
KR102666639B1 (en) 2024-05-20
CN112566658A (en) 2021-03-26

Similar Documents

Publication Publication Date Title
PH12021550319A1 (en) Escherichia coli compositions and methods thereof
EA201691478A1 (en) NEW POLYSACCHARIDE AND ITS APPLICATIONS
EA201890400A1 (en) METHODS AND COMPOSITIONS FOR IMMUNE PROTECTION AGAINST EXTRAUCTAL PATHOGENIC E. COLI
MX2023001948A (en) Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates.
PH12020500080A1 (en) Senecavirus a immunogenic compositions and methods thereof
MX2018001213A (en) Novel methods for inducing an immune response.
BR112020004509A8 (en) POLYSACCHARIDE-CARRIER PROTEIN CONJUGATE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME AND USE OF SAID CONJUGATE
CY1121535T1 (en) USPA2 PROTEIN PRODUCTS AND THEIR USES
SG10202101887WA (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
BR112015008419A2 (en) immunogenic composition and vaccine
MX2021013109A (en) Process for preparing an attenuated tetravalent dengue vaccine.
MX2018011291A (en) Neisseria meningitidis compositions and methods thereof.
MX2023004834A (en) Expec glycoconjugate vaccine formulations.
MX2016007316A (en) Prevention of staphylococcus aureus infections by glycoprotein vaccines synthesized in escherichia coli.
ZA202103560B (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
TN2019000064A1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
BR112013021870A2 (en) mixed tetravalent and bivalent dengue vaccine
PH12018500675A1 (en) Stable live attenuated recombinant dengue vaccine
BR112018074910A2 (en) immunological composition, and method of inducing an immune response against equine influenza virus in a subject
MX2021005500A (en) Multivalent glycoconjugates immunogenic compositions.
MX2020007246A (en) Comprehensive vaccine design for commensal disease progression.
WO2019022611A3 (en) Enhancement of pathogen immunogenicity
WO2019157188A3 (en) Compositions and methods for cross-protection against pneumococcal disease
AR116010A1 (en) ESCHERICHIA COLI COMPOSITIONS AND METHODS OF THEM